Pembrolizumab Provides “Robust” Clinical Benefit in Clear Cell Gynecologic Cancer
“Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
Related Articles
SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors
An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care
Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.
Menin inhibitors in the treatment of acute myeloid leukemia
In this Blood Spotlight, Huls et al highlight why small molecule inhibitors of menin are creating excitement in the acute myeloid leukemia (AML) field with
NIH Cuts Indirect Cost Payments: “Lights in Labs Nationwide Will Literally Go Out”
The NIH said capping indirect cost payments will save billions of dollars. Universities said it will disrupt vital, life-saving research.
Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC
Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.
Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL
Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.
Asciminib for Ph+ ALL: a step forward?
In this issue of Blood, Luskin et al present results of the first phase 1 trial combining asciminib, an allosteric BCR::ABL1 inhibitor, with the tyrosine k
Sallman on Eprenetapopt and Azacitidine in TP53-Mutant MDS/AML
David Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.
Protocol Reduces Side Effects Before Myeloma Transplant : Oncology Times
An abstract is unavailable.
